Triazine Compounds for Selective PI3K and mTOR Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K and mTOR inhibitors, while effective in cancer treatment, often have non-linear pharmacokinetic profiles and may cause unwanted side effects due to lack of selectivity, necessitating the development of more potent, fully synthetic compounds with improved pharmacokinetic behaviors.
Innovation Solution
Development of novel 2,4,6-substituted [1,3,5]triazine compounds that inhibit PI3 kinases and mTOR, specifically designed to have enhanced selectivity and improved pharmacokinetic properties, including compounds of formula I with specific substituents that act as inhibitors of mTOR and PI3 kinases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PI3K and mTOR inhibitors are used for cancer treatment, then cancer treatment effectiveness is achieved, but non-linear pharmacokinetic profiles and unwanted side effects occur due to lack of selectivity
Solution Approach 1:
The patent applies local quality by designing triazine compounds with specific substituent patterns (morpholino, tetrahydropyranyl, or dihydropyranyl groups at defined positions) that create localized interactions with PI3K and mTOR binding sites. This structural specificity enables selective inhibition of these targets while minimizing off-target effects, resolving the contradiction between treatment effectiveness and side effect reduction
Solution Approach 2:
The patent employs parameter changes by systematically varying the substituents on the triazine core structure to optimize pharmacokinetic properties. By adjusting parameters such as lipophilicity, molecular weight, and hydrogen bonding capacity through different substituent combinations, the compounds achieve improved pharmacokinetic profiles while maintaining potent and selective inhibition of PI3K and mTOR
2Reliability
If existing PI3K and mTOR inhibitors are used, then inhibition of target enzymes is achieved, but selectivity is insufficient leading to off-target effects
Solution Approach 1:
The patent achieves enhanced selectivity through local quality by incorporating specific functional groups (morpholino, tetrahydropyranyl, dihydropyranyl) at precise positions on the triazine ring. These localized structural features create specific molecular recognition patterns that distinguish PI3K and mTOR from other kinases, enabling selective inhibition while maintaining potent enzymatic activity
Solution Approach 2:
The patent applies asymmetry by using asymmetric substituent patterns on the triazine core, where different groups are placed at specific positions (e.g., morpholino at one position and tetrahydropyranyl at another). This asymmetric arrangement creates chiral-like recognition patterns that enhance selectivity for PI3K and mTOR over other kinases, resolving the contradiction between inhibition efficacy and selectivity
Data Source
AI summary
Compounds of formula Iwherein:R1 isand R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.